Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof

US7153882B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• The National Institutes of Health and Axonyx, Inc. · US

Inventors

• Nigel H. Greig · Phoenix, US
• Karen T. Y. Shaw · Mont-Laurier, CA
• Qiang Yu · Shanghai, CN
• Harold W. Holloway · Middle River, US
• Timothy T. Sencrant · Silver Spring, US
• Tada Utsuki · West Chester, US
• Donald K. Ingram · Ellicott City, US
• Arnold Brossi · Bethesda, US
• Anthony Giordano · Shreveport, US
• Gordon Powers · Malvern, US
• Diane Davidson · Collegeville, US
• Michael Sturgess · Quakertown, US

Key dates

• Filing date: Nov 2, 2001
• Grant date: Dec 26, 2006
• Expiry date: Dec 23, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.